BRCA2 and ovarian carcinoma: Moreover, most currently used DNA assays fail to detect epigenetic modifications (such as promoter hypermethylation), as well as mutations located deep within introns that may alter the mRNA [17].Here, we hypothesized that measuring the level of BRCA1 and BRCA2 mRNA in ovarian cancer tissue may provide additional information when DNA tests are negative or inconclusive.